The Upjohn Company and Pharmacia Aktiebolag; Consent Agreement With Analysis to Aid Public Comment

Короткий зміст

In settlement of alleged violations of federal law prohibiting unfair acts and practices and unfair methods of competition, this consent agreement, accepted subject to final Commission approval, would require The Upjohn Company and Pharmacia Aktiebolag to divest Pharmacia's assets in ``9-AC,'' a topoisomerase I inhibitor drug for the treatment of colorectal cancer, to a Commission-approved buyer who will ensure that research and development will continue in competition with the merged company's product ``CPT-11,'' a topoisomerase I inhibitor drug developed by Upjohn.